[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adaptive Biotechnologies Corp 1165 EASTLAKE AVENUE EAST SUITE 200 SEATTLE WA 98109 USA

www.adaptivebiotech.com Employees: 624 P: 206-659-0067 F: 206-659-0667

Sector:

Medical

Description:

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 2,210,208
Enterprise Value, $K 2,139,708
Shares Outstanding, K 160,044
Float, K 150,922
% Float 94.30%
Short Interest, K 8,551
Short Float 5.34%
Days to Cover 4.41
Short Volume Ratio 0.43
% of Insider Shareholders 5.70%
% of Institutional Shareholders 99.17%

Financials:

Annual Sales, $ 276,980 K
Annual Net Income, $ -59,500 K
Last Quarter Sales, $ 71,680 K
Last Quarter Net Income, $ -13,580 K
EBIT, $ -55,420 K
EBITDA, $ -40,100 K

Growth:

1-Year Return 49.94%
3-Year Return 113.78%
5-Year Return -60.02%
5-Year Revenue Growth 181.54%
5-Year Earnings Growth 45.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.13 on 05/05/26
Next Earnings Date 08/04/26
Earnings Per Share ttm -0.61
EPS Growth vs. Prev Qtr -44.44%
EPS Growth vs. Prev Year 35.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ADPT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -40.06%
Return-on-Assets % -16.64%
Profit Margin % -21.48%
Debt/Equity 0.00
Price/Sales 8.49
Price/Cash Flow N/A
Price/Book 10.47
Book Value/Share 1.47
Interest Coverage -4.05
60-Month Beta 2.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.